Stay updated on Injectable Cabotegravir vs TDF/FTC in MSM Clinical Trial

Sign up to get notified when there's something new on the Injectable Cabotegravir vs TDF/FTC in MSM Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Injectable Cabotegravir vs TDF/FTC in MSM Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Added a site-wide notice about government funding and NIH Clinical Center status; updated page revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-02-04T06:55:25.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    Added: Show glossary, Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, Revision: v3.4.0. Removed or renamed: Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4.
    Difference
    0.2%
    Check dated 2026-01-28T04:55:23.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The page shows a minor revision update from v3.3.3 to v3.3.4; no study content changes were made. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T01:31:49.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    A new final publication entry for Brown et al. (Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083) is added to Publications, and the prior online-ahead-of-print listing is removed.
    Difference
    0.0%
    Check dated 2026-01-06T22:59:45.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    Locations section updated to add new study sites across multiple US states and international locations (examples include Alabama, California, Buenos Aires, São Paulo, Bangkok, Western Cape, and more). The HHS Vulnerability Disclosure link was removed.
    Difference
    2%
    Check dated 2025-12-23T10:22:09.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    Added a PubMed auto-fill notice for publications and updated the page revision to v3.3.2; removed the older PubMed note and the v3.2.0 revision label.
    Difference
    0.1%
    Check dated 2025-11-24T17:02:34.000Z thumbnail image

Stay in the know with updates to Injectable Cabotegravir vs TDF/FTC in MSM Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Injectable Cabotegravir vs TDF/FTC in MSM Clinical Trial page.